A phase I/II trial of BNC105P with everolimus in metastatic renal cell carcinoma (mRCC)

PURPOSE: BNC105P inhibits tubulin polymerization, and preclinical studies suggest possible synergy with everolimus. In this phase I/II study, efficacy and safety of the combination were explored in patients with metastatic renal cell carcinoma (mRCC). EXPERIMENTAL DESIGN: A phase I study in patients...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Clin Cancer Res
Main Authors: Pal, Sumanta, Azad, Arun, Bhatia, Shailender, Drabkin, Harry, Costello, Brian, Sarantopoulos, John, Kanesvaran, Ravindran, Lauer, Richard, Starodub, Alexander, Hauke, Ralph, Sweeney, Christopher J., Hahn, Noah M., Sonpavde, Guru, Richey, Stephen, Breen, Timothy, Kremmidiotis, Gabriel, Leske, Annabell, Doolin, Elizabeth, Bibby, David C., Simpson, Jeremy, Iglesias, Jose, Hutson, Thomas
Format: Artigo
Jezik:Inglês
Izdano: 2015
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4526387/
https://ncbi.nlm.nih.gov/pubmed/25788492
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-14-3370
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki